CTXA8 CAR T / VRG Therap - LARVOL DELTA

VRG Therapeutics announces successful in vivo efficacy results of their CAR-T project targeting glioblastoma (EIN News) - "VRG Therapeutics Plc. announces successful in vivo efficacy results of their CAR-T project with patented chlorotoxin analogue targeting glioblastoma, encouraging further development....VRG Tx’s animal in vivo proof of concept (PoC) study: VRG Tx established a heterotopic xenograft mice model to demonstrate the effectiveness and safety of its CTXA8-targeting CAR-T cell therapy that is designed to treat patients with glioblastoma multiforme (a common type of brain tumor)....CTXA8-CAR-T cells showed effective tumor growth inhibition compared to non-specific T cell controls at three different dose levels. The highest dose of administered CTXA8-CAR-T resulted in over 60% inhibition of tumor growth including two individuals with complete tumor remission."

Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

VRG announces major milestone in chlorotoxin targeted CAR T therapy in glioblastoma (EIN News) - "Vascular Research Group...announced that their proprietary chlorotoxin (CTX) analogue, CTXA8, an antigen recognition domain in CAR T-cells, shows high potency in eliminating glioblastoma multiforme (GBM) cells in a preclinical in vitro GBM model. CTXA8 CAR modified T-cells demonstrated superior efficacy over the CAR T candidate employing natural CTX currently in a Phase 1 clinical trial...VRG’s latest results show that CTXA8 CAR T-cells demonstrate faster and improved killing of tumor cells within 24 hours with an effector-target ratio of 1:3, which predicts higher efficacy and lower off-tumor effect compared to the CAR T therapy with original CTX currently in Phase 1. The increased efficacy of CTXA8-based CAR T therapy is due to the increased affinity and selectivity of CTXA8 versus original CTX towards MMP2 overexpressing tumor cells. This is further supported by a cytokine release assay in which CTXA8 CAR T-cells secreted 3 times more IFN gamma than CTX CAR Ts."

Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor